Keytruda shown to improve tumor response, extend lives of people with advanced melanoma
An international team of researchers led by doctors at UCLA has found that pembrolizumab (Keytruda®) improved tumor responses, duration of responses and extended the patient's life compared to the current standard of care treatment with ipilimumab (Yervoy®) for people with advanced melanoma. April 19, 2015